Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at B.Riley/FBR
March 8, 2019 6:57 AM ESTB.Riley/FBR analyst Harshita Polishetty lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $26.00 (from $40.00) while maintaining a Buy rating following 4Q report.
On the earnings call, management noted that the company has currently decided to defer the advancement of the entinostat-PD-1... More
Syndax Pharmaceuticals (SNDX) Misses Q4 EPS by 3c; Provides Q1 & FY19 Operating Guidance
March 7, 2019 4:27 PM ESTSyndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.70), $0.03 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $380 thousand versus the consensus estimate of $390 thousand.
"We expect the coming months to be a very exciting, milestone-rich time for Syndax as we continue to work towards our mission of realizing a future in which cancer patients live longer and better lives than previously possible," said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. "We remain highly encouraged by the potential for a positive overall survival readout in E2112, our Phase 3... More
